March 8, 2018
Late-winter weather got you down? Curl up fireside with one of two new KI research reviews. In Nature Reviews Cancer, Stefani Spranger, the Howard S. (1953) and Linda B. Stern Career Development Professor, helps uncover the mystery behind which tumors respond to cancer immunotherapies called checkpoint blockades, and how activation of certain signaling pathways in tumor cells can impair local antitumor immune responses. Mystery not your genre? ACS Nano recently featured a page-turner by members of the Langer lab and their collaborators describing recent advances in drug delivery, materials science, and nanotechnology to develop next-generation nanoparticle platforms to overcome barriers for delivery of TRAIL. TRAIL is an immune molecule that has received significant attention as a cancer therapeutic because it can selectively trigger cancer cell apoptosis — or cell suicide — without causing toxicity, but creating viable delivery systems is no linear plot. The team has received support from the S. Leslie Misrock (1949) Fund for Cancer Nanotechnology, the Bridge Project, and the Marble Center for Cancer Nanomedicine.